Company intelligence / Profile preview
Sangart
San Diego, California, United Statessangart.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MP4OX failed in Phase 2b study for trauma patients, not showing statistically significant improvement in the primary endpoint of patients discharged and alive after 28 days compared to standard care. MP4CO completed a successful Phase 1b trial for sickle cell disease[2][4].
- Therapeutic areas
- HematologyCardiovascular
- Modalities
- Oxygen-therapeutic agentshemoglobin-based products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Sangart.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sangart.